Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.

Luca Cantini,Mirco Pistelli,Filippo Merloni,Andrea Fontana,Ilaria Bertolini,Claudia De Angelis,Lucia Bastianelli,Arianna Della Mora,Alfredo Santinelli,Agnese Savini,Elena Maccaroni,Lucrezia Diodati,Alfredo Falcone,Rossana Berardi

Clinical Breast Cancer（2020）

引用 8|浏览25

暂无评分

摘要

Our real-life data highlight a different risk of eBC recurrence after grouping patients according to HR status and BMI. These results might help clinicians to identify correct treatment strategies. Patients who are HR and have BMI ≥25 might benefit from escalation approaches, whereas those who are HR and have BMI <25 might be eligible for a shorter duration of adjuvant treatment with anti-HER2 agents.

查看译文

关键词

Body mass index,Early breast cancer,HER2,Hormone receptors,Trastuzumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要